



# CPT® Administrative Codes for Multianalyte Assays with Algorithmic Analyses

It is important to note that further CPT Editorial Panel (Panel) or Executive Committee actions may affect these codes and/or descriptors. For this reason, code numbers and/or descriptor language in the CPT code set may differ at the time of publication. In addition, further Panel actions may result in gaps in code number sequencing.

### Most recent changes to the CPT® Administrative MAAAs Long Descriptor document

- There are no changes to report for the October 2021 Administrative Multianalyte Assays with Algorithmic Analyses (MAAA) codes early release.

Proprietary Name and Clinical Laboratory or Manufacturer	Code	Long Code Descriptor	Released to AMA Website	Effective	Publication
<b>The following code was accepted at the October 2020 CPT Editorial Panel meeting for the 2022 CPT production cycle. This code will be effective on January 1, 2021.</b>					
Lymph2Cx, Mayo Clinic Arizona Molecular Diagnostics Laboratory	●0017M	Oncology (diffuse large B-cell lymphoma [DLBCL]), mRNA, gene expression profiling by fluorescent probe hybridization of 20 genes, formalin-fixed paraffin-embedded tissue, algorithm reported as cell of origin  ▶(Do not report 0017M in conjunction with 0120U) ◀	December 1, 2020	January 1, 2021	CPT® 2022
<b>The following code was accepted at the May 2021 CPT Editorial Panel meeting for the 2022 CPT production cycle. This code will be effective on October 1, 2021.</b>					
Pleximark™, Plexision, Inc	●0018M	Transplantation medicine (allograft rejection, renal), measurement of donor and third-party-induced CD154+T-cytotoxic memory cells, utilizing whole peripheral blood, algorithm reported as a rejection risk score  ▶(Do not report 0018M in conjunction with 85032, 86353, 86821, 88184, 88185, 88187, 88230, 88240, 88241) ◀	July 1, 2021	October 1, 2021	CPT® 2022